{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T11:15:33Z","timestamp":1753355733517,"version":"3.37.3"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T00:00:00Z","timestamp":1695686400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T00:00:00Z","timestamp":1695686400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Baxalta Innovations GmbH, a Takeda company"},{"DOI":"10.13039\/100016469","name":"Takeda Pharmaceuticals International AG","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100016469","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s12325-023-02649-0","type":"journal-article","created":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T09:02:27Z","timestamp":1695718947000},"page":"5168-5187","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Real-World Use, Safety, and Patient Experience of 20% Subcutaneous Immunoglobulin for Primary Immunodeficiency Diseases"],"prefix":"10.1007","volume":"40","clinical-trial-number":[{"clinical-trial-number":"drks00014562","registry":"10.18810\/drks"}],"author":[{"given":"Maria","family":"Fasshauer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Borte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michaela","family":"Bitzenhofer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Pausch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Pittrow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9","family":"Gladiator","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Jandus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,9,26]]},"reference":[{"issue":"1","key":"2649_CR1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s41232-021-00159-6","volume":"41","author":"M Yamashita","year":"2021","unstructured":"Yamashita M, Inoue K, Okano T, Morio T. Inborn errors of immunity-recent advances in research on the pathogenesis. Inflamm Regen. 2021;41(1):9.","journal-title":"Inflamm Regen"},{"issue":"7","key":"2649_CR2","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1007\/s10875-022-01289-3","volume":"42","author":"SG Tangye","year":"2022","unstructured":"Tangye SG, Al-Herz W, Bousfiha A, Cunningham-Rundles C, Franco JL, Holland SM, et al. Human inborn errors of immunity: 2022 update on the classification from the International Union of Immunological Societies expert committee. J Clin Immunol. 2022;42(7):1473\u2013507.","journal-title":"J Clin Immunol"},{"key":"2649_CR3","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.3389\/fimmu.2019.01272","volume":"10","author":"SM El-Helou","year":"2019","unstructured":"El-Helou SM, Biegner AK, Bode S, Ehl SR, Heeg M, Maccari ME, et al. The German national registry of primary immunodeficiencies (2012\u20132017). Front Immunol. 2019;10:1272.","journal-title":"Front Immunol."},{"issue":"1","key":"2649_CR4","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/cei.12661","volume":"182","author":"K Marschall","year":"2015","unstructured":"Marschall K, Hoernes M, Bitzenhofer-Gruber M, Jandus P, Duppenthaler A, Wuillemin WA, et al. The Swiss National Registry for Primary Immunodeficiencies: report on the first 6 years\u2019 activity from 2008 to 2014. Clin Exp Immunol. 2015;182(1):45\u201350.","journal-title":"Clin Exp Immunol"},{"issue":"Suppl 1","key":"2649_CR5","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/j.1365-2249.2009.04027.x","volume":"158","author":"S Misbah","year":"2009","unstructured":"Misbah S, Sturzenegger MH, Borte M, Shapiro RS, Wasserman RL, Berger M, et al. Subcutaneous immunoglobulin: opportunities and outlook. Clin Exp Immunol. 2009;158(Suppl 1):51\u20139.","journal-title":"Clin Exp Immunol"},{"key":"2649_CR6","unstructured":"European Medicines Agency. Cuvitru 200 mg\/ml solution for subcutaneous injection. Summary of product characteristics. 2022. Available from: https:\/\/www.medicines.org.uk\/emc\/product\/9191\/smpc. Accessed 6 Sept 2023."},{"key":"2649_CR7","unstructured":"United States Food and Drug Administration. Cuvitru, Immune globulin subcutaneous (human) 20% solution. Prescribing information. 2021. Available from: https:\/\/www.fda.gov\/media\/100531\/download. Accessed 6 Sept 2023."},{"issue":"1","key":"2649_CR8","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1111\/cei.12866","volume":"187","author":"M Borte","year":"2017","unstructured":"Borte M, Krivan G, Derfalvi B, Marodi L, Harrer T, Jolles S, et al. Efficacy, safety, tolerability and pharmacokinetics of a novel human immune globulin subcutaneous, 20%: a phase 2\/3 study in Europe in patients with primary immunodeficiencies. Clin Exp Immunol. 2017;187(1):146\u201359.","journal-title":"Clin Exp Immunol"},{"issue":"7","key":"2649_CR9","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1007\/s10875-016-0327-9","volume":"36","author":"D Suez","year":"2016","unstructured":"Suez D, Stein M, Gupta S, Hussain I, Melamed I, Paris K, et al. Efficacy, safety, and pharmacokinetics of a novel human immune globulin subcutaneous, 20% in patients with primary immunodeficiency diseases in North America. J Clin Immunol. 2016;36(7):700\u201312.","journal-title":"J Clin Immunol"},{"issue":"5","key":"2649_CR10","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.anai.2021.06.023","volume":"127","author":"LM Meckley","year":"2021","unstructured":"Meckley LM, Wu Y, Tzivelekis S, Gandhi V, Gladiator A. Infusion parameters of 20% subcutaneous immunoglobulin for primary immunodeficiency diseases among patient support program participants. Ann Allergy Asthma Immunol. 2021;127(5):568\u201374e1.","journal-title":"Ann Allergy Asthma Immunol."},{"issue":"1","key":"2649_CR11","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s13223-022-00709-8","volume":"18","author":"PK Keith","year":"2022","unstructured":"Keith PK, Cowan J, Kanani A, Kim H, Lacuesta G, Lee JK, et al. Transitioning subcutaneous immunoglobulin 20% therapies in patients with primary and secondary immunodeficiencies: Canadian real-world study. Allergy Asthma Clin Immunol. 2022;18(1):70.","journal-title":"Allergy Asthma Clin Immunol"},{"key":"2649_CR12","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1007\/s10875-023-01436-4","volume":"43","author":"K Rosenbach","year":"2023","unstructured":"Rosenbach K, Park M, Sanchirico M, Nwose O, Paris K. Real-world evidence of tolerability of 20% subcutaneous immunoglobulin treatment. J Clin Immunol. 2023;43:912.","journal-title":"J Clin Immunol"},{"issue":"5","key":"2649_CR13","first-page":"504","volume":"67","author":"PB Daly","year":"1991","unstructured":"Daly PB, Evans JH, Kobayashi RH, Kobayashi AL, Ochs HD, Fischer SH, et al. Home-based immunoglobulin infusion therapy: quality of life and patient health perceptions. Ann Allergy. 1991;67(5):504\u201310.","journal-title":"Ann Allergy"},{"issue":"7","key":"2649_CR14","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1007\/s11136-005-1746-x","volume":"14","author":"U Nicolay","year":"2005","unstructured":"Nicolay U, Haag S, Eichmann F, Herget S, Spruck D, Gardulf A. Measuring treatment satisfaction in patients with primary immunodeficiency diseases receiving lifelong immunoglobulin replacement therapy. Qual Life Res. 2005;14(7):1683\u201391.","journal-title":"Qual Life Res"},{"key":"2649_CR15","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1477-7525-2-12","volume":"2","author":"MJ Atkinson","year":"2004","unstructured":"Atkinson MJ, Sinha A, Hass SL, Colman SS, Kumar RN, Brod M, et al. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes. 2004;2:12.","journal-title":"Health Qual Life Outcomes"},{"key":"2649_CR16","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/1477-7525-7-36","volume":"7","author":"M Bharmal","year":"2009","unstructured":"Bharmal M, Payne K, Atkinson MJ, Desrosiers MP, Morisky DE, Gemmen E. Validation of an abbreviated Treatment Satisfaction Questionnaire for Medication (TSQM-9) among patients on antihypertensive medications. Health Qual Life Outcomes. 2009;7:36.","journal-title":"Health Qual Life Outcomes"},{"issue":"3","key":"2649_CR17","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.anai.2019.06.004","volume":"123","author":"S Gupta","year":"2019","unstructured":"Gupta S, Stein M, Hussain I, Paris K, Engl W, McCoy B, et al. Tolerability of Ig20Gly during onboarding in patients with primary immunodeficiency diseases. Ann Allergy Asthma Immunol. 2019;123(3):271\u20139e1.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2649_CR18","unstructured":"European Medicines Agency. Hizentra 200 mg\/ml solution for subcutaneous injection. Summary of product characteristics. 2022. Available from: https:\/\/www.medicines.org.uk\/emc\/product\/4643\/smpc. Accessed 6 Sept 2023."},{"key":"2649_CR19","unstructured":"United States Food and Drug Administration. Immune globulin subcutaneous (human) (IGSC), 20% liquid, Hizentra. Prescribing information. 2021. Available from: https:\/\/www.fda.gov\/media\/78466\/download. Accessed 6 Sept 2023."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02649-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-023-02649-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02649-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T11:07:43Z","timestamp":1698404863000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-023-02649-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,26]]},"references-count":19,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["2649"],"URL":"https:\/\/doi.org\/10.1007\/s12325-023-02649-0","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"type":"print","value":"0741-238X"},{"type":"electronic","value":"1865-8652"}],"subject":[],"published":{"date-parts":[[2023,9,26]]},"assertion":[{"value":"8 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Maria Fasshauer has participated in advisory boards for Baxalta\/Shire, has received honoraria for lectures from CSL Behring and Shire, and has received travel grants from Octapharma until 2018. Michael Borte\u2019s institution has received research grant support from Baxalta, CSL Behring, and Octapharma, and he has participated in advisory boards for CSL Behring, Octapharma, and Shire. Michaela Bitzenhofer has received a grant from Takeda. Christine Pausch has nothing to disclose. David Pittrow reports personal fees from Amgen, Aspen, Bayer, Biogen, Boehringer Ingelheim, Daiichi Sankyo, Janssen, MSD, Sandoz, and Sanofi Genzyme outside the submitted work. He has acted as a consultant for Baxalta. Michelle Park is an employee of Takeda Development Center Americas, Inc. and a Takeda shareholder. Andr\u00e9 Gladiator is an employee of Takeda Pharmaceuticals International AG and a Takeda shareholder. Peter Jandus has participated in advisory boards for AstraZeneca, CSL Behring, GSK, Sanofi, and Shire, has received honoraria for lectures from CSL Behring and Shire, has received travel grants from Biotest, CSL Behring, Octapharma, and Shire, and has received research grants to his institution from AstraZeneca, CSL Behring, Novartis, and Shire.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study was conducted in accordance with the International Council for Harmonization Good Clinical Practice, the Declaration of Helsinki 1964 and national and local laws and regulations. Ethics approval was given by the ethics committee of Saxony Physician Chamber and Swissethics (EK-BR-12\/18-1). The study is registered in the German Clinical Trials Register under the identifier DRKS00014562. All patients or their legally authorized representative provided written informed consent to participate and consent for publication prior to study enrollment.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}